About Dizal Pharma
Dizal Pharma is a publicly listed company based in Pudong (China) founded in 2017. Pharmaceutical research and development are focused on oncology therapeutics. Dizal Pharma has raised $100 million across 1 funding round from investors including SANY Group, Lilly Asia Ventures and Trinity Innovation Fund. Its focus areas include Pharmaceutical Distributors and Diversified. Its competitors include Quanyuantang Pharmacy, Guiyang Xintian Pharmaceutical and Sinopharm Online; 2 of its 3 listed competitors have raised funding.
Company details
Dizal Pharma was founded in 2017 and is headquartered in Pudong, China. Operations are centered in the biopharmaceutical sector, with emphasis on discovering and developing novel small-molecule drugs for oncology and other unmet medical needs. Clinical-stage assets are advanced through partnerships and internal RD efforts, targeting global markets while maintaining a base in Asia. Limited public details are available on specific services or revenue streams.
- Headquarters Pudong, China
- Stage Public
- SectorsHealthcare
- Website dizalpharma.com
- Social LinkedIn
- Legal Name Dizal (Jiangsu) Pharmaceutical Co. Ltd. Class A
- Annual Revenue$114.34 M (USD)122.77as on Dec 31, 2025
- Net Profit-$109.13 M (USD)9.68as on Dec 31, 2025
- EBITDA-$106.41 M (USD)16.92as on Dec 31, 2025
- Total Equity Funding$100M (USD)
in 1 rounds
- Latest Funding Round$100M (USD), Series A
Aug 2020
- InvestorsSANY Group
& 3 more
Funding Insights of Dizal Pharma
Dizal Pharma has successfully raised a total of $100M through 1 strategic funding round. The most recent funding activity was a Series A round of $100 million completed in August 2020. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $100M
- Total Rounds 1
- Last Round Series A — $100M
- First Round $100M
(Aug 2020)
- Investors Count 4
All 1 funding rounds of Dizal Pharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Aug 2020 | $100M | Series A | – | Lilly Asia Ventures |
4 investors in total: 4 institutional.
Investors in Dizal Pharma
Dizal Pharma has secured backing from 4 investors, including institutional and venture fund investors. Prominent investors backing the company include SANY Group, Lilly Asia Ventures and Trinity Innovation Fund.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
A venture capital firm focused on biotech innovation investments. | 2018 | trinity-fund.com | Beijing, China | |
| lillyasiaventures.com | ||||
Manufacturer of construction & mining equipment, port, and oil drilling machinery | 1989 | sanyglobal.com | Changsha, China | |
HongShan is engaged in venture capital investments for innovative companies. | hongshan.com | Hong Kong, China |
Investor details for Dizal Pharma
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of Dizal Pharma
16 people are tracked at Dizal Pharma (11 in leadership, 5 in team).
| Name | Role | Group |
|---|---|---|
Zongming Guo（郭宗明） | Head of ISIT Associate Director | Leadership |
Pamela Yang | Chief Medical Officer | Leadership |
Xiaolin Zhang | Founder, Chairman, CEO | Leadership |
Qingyi (Anita) Wu | Chief Commerical Officer | Leadership |
Vera Song | VP, Business Unit Head | Leadership |
frank lu | Director, general lab operation | Leadership |
天伟 张 | Project Management Associate Director | Leadership |
Honchung T. | Chemistry, VP | Leadership |
Violet Zhang | VP, Head of Operation | Leadership |
Susan Chen | Sr VP, Clinical Operation | Leadership |
Changhe Qi | Senior Director, Medicinal Chemistry | Leadership |
Yu Bai | Project Leader | Team |
Jason Li | Medical Scientist - Senior Medical Scientist - Clinical research physician | Team |
Letty Zhao | HR Ops | Team |
Quan Zhou | Project Leader/Senior Investigator I | Team |
Zhijian Sun | Manufacture Project Leader | Team |
Complete people profiles for Dizal Pharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Dizal Pharma
Dizal Pharma is a publicly listed company on the SSE with ticker symbol 688192 in China, operating in the Commercial services sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date10 Dec 2021
- Listed onSSE: 688192
- Listed entityDizal (Jiangsu) Pharmaceutical Co. Ltd. Class A
- Exchange sectorCommercial services
- ISINCNE1000055W8
- Share price60.69 CNY (-1.95% on the day) · 2026-10-14
- Market capitalisation28,793,765,743.00 CNY
- EPS (diluted, trailing year)-1.29 CNY
- Volume (last session)5,683,360
Financials of Dizal Pharma
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | 800.5M CNY | -764.0M CNY | -745.0M CNY |
| 2024 | 359.3M CNY | -846.0M CNY | -896.8M CNY |
| 2023 | 90.9M CNY | -1.11B CNY | -1.08B CNY |
| 2022 | -736.0M CNY | -729.7M CNY | |
| 2021 | 10.1M CNY | -669.9M CNY | -619.1M CNY |
Detailed financial statements for Dizal Pharma
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of Dizal Pharma
3 dated milestones of Dizal Pharma across 4 years, from founding to its latest funding, stage changes and deals.
- Founded Dizal Pharma is founded.
- Funding First funding round of $100.0M.
- IPO Lists on the stock exchange (IPO).
Competitors of Dizal Pharma
Dizal Pharma has 3 listed competitors in our database, 2 of them funded. They include Quanyuantang Pharmacy, Guiyang Xintian Pharmaceutical and Sinopharm Online.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| qyt1902.com | 1902 | Chengdu, China | $76.05M | Medical and pharmaceutical products are retailed offline and online. | ||
| gyxtyy.com | 1995 | Guiyang, China | Pharmaceutical company in China | |||
| yao123.cn | 2015 | Minhang, China | $62.35M | Pharmaceutical products are sold via an e-commerce platform in China. |
Detailed competitors of Dizal Pharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Dizal Pharma
The website of Dizal Pharma (dizalpharma.com) receives about 4.3K visits a month.
- Monthly visits4.3K
▼ 16.2% vs previous month
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Dizal Pharma
Complete news archive for Dizal Pharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Dizal Pharma
Dizal Pharma was founded in 2017 and raised its 1st funding round 3 years after it was founded.
Dizal Pharma is headquartered in Pudong, China. It is registered at Pudong, Shanghai, China.
Dizal Pharma is a funded company, having raised a total of $100M across 1 funding round to date. The company's 1st funding round was a Series A of $100M, raised on Aug 2020.
Annual revenue of Dizal Pharma is $114.34M as on Dec 31, 2025.
Dizal Pharma was founded in 2017 and is headquartered in Pudong, China. Operations are centered in the biopharmaceutical sector, with emphasis on discovering and developing novel small-molecule drugs for oncology and other unmet medical needs. Clinical-stage assets are advanced through partnerships and internal RD efforts, targeting global markets while maintaining a base in Asia. Limited public details are available on specific services or revenue streams.
Dizal Pharma's top competitors include Guiyang Xintian Pharmaceutical, Quanyuantang Pharmacy and Sinopharm Online.
Yes, Dizal Pharma is publicly traded on SSE under the ticker symbol 688192.
Dizal Pharma has 4 investors. Key investors include SANY Group, Lilly Asia Ventures, Trinity Innovation Fund, and HongShan.